What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to provide investors with supplemental historical financial information presented under a new, revised reportable segment structure. This change is intended to offer a clearer view of the company's operational performance and resource allocation.

Will these segment changes affect McKesson's past financial results or reported earnings per share?

No, the filing explicitly states that these segment changes did not impact the previously issued consolidated financial statements nor the earnings per common share of McKesson for historical periods. The changes are primarily for reporting and analytical purposes going forward.

Why is McKesson making these segment changes?

The changes are driven by an evaluation of the company's management and operating structure, particularly following the retirement of the segment manager for Distribution Solutions. The new structure reflects how the Chief Operating Decision Maker (CODM) allocates resources and assesses performance starting in the first quarter of fiscal year 2019.

MCK 8-K SEC Disclosure — May 24, 2018

Q: What are the new reportable segments for McKesson?

McKesson will now report its financial results in three primary segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. Any remaining business activities that are not significant enough to warrant separate disclosure will be grouped under 'Other'.

Summary

McKesson Corporation (MCK) has filed an 8-K report to provide investors with supplemental historical financial information, restated under a new reportable segment structure. This realignment, effective from the first quarter of fiscal year 2019, is a result of a strategic evaluation of the company's management and operating structure following the retirement of a key executive. The new segment structure, which will be applied retrospectively for historical periods, comprises U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. All other business activities will be consolidated into an 'Other' category. This change is intended to provide investors with a clearer understanding of how the company allocates resources and assesses performance, aligning with the chief operating decision maker's perspective. The report also highlights that these segment changes do not alter previously reported consolidated financial statements or earnings per share.

Key Highlights

1McKesson is restating historical financial data to reflect a new, simplified three-reportable-segment structure: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions.
2This segment realignment is effective from the first quarter of fiscal year 2019 and is a response to changes in the company's management and operating structure.
3The new segments better align with how McKesson's Chief Operating Decision Maker (CODM) allocates resources and evaluates performance.
4Historical financial information for fiscal years ended March 31, 2018, 2017, and 2016, and for fiscal quarters ending June 30, 2017, September 30, 2017, December 31, 2017, and March 31, 2018, will be presented under the new structure.
5The 'Other' segment will encompass McKesson Canada, McKesson Prescription Technology Solutions, and the company's 70% equity interest in Change Healthcare.
6These segment changes are primarily a reporting and organizational update and do not impact previously issued consolidated financial statements or earnings per share.
7Supplemental financial information conforming to the new segment structure is included as an exhibit (Exhibit 99.1).

MCKESSON CORP 8-K Report, Corporate Update (May 24, 2018)

Summary

Key Highlights

Frequently Asked Questions